Peptomyc
Manufacturing · Spain · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Av Republica Argentina 9 Pta.1, Barcelon...Website
www.peptomyc.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Peptomyc
Peptomyc is a pioneering biotechnology company focused on developing innovative MYC inhibitors to treat cancer, specifically utilizing mini-protein therapeutics to directly inhibit MYC, a key driver of cancer proliferation and resistance. The company aims to improve patient survival and quality of life for those with abnormal MYC activity through its first-in-class drug, OMO-103, which has shown promising results in clinical trials. Peptomyc targets a significant unmet medical need in cancer treatment, particularly for patients with pancreatic ductal adenocarcinoma (PDAC) and other cancers driven by MYC dysregulation. With a dedicated team and a strong network of advisors, Peptomyc is positioned to transform the cancer treatment landscape.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Peptomyc your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Peptomyc is spiking on competitors!
Click to see if Peptomyc had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Peptomyc, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Peptomyc
Earning: See what the market has to say on Peptomyc recently announced quarterly report
Check if Peptomyc has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Peptomyc has new funding data
Product Launch: Get notified when Peptomyc launches new products
Recommended Actions
Find VP level buyers at Peptomyc
Find 2 more new buyers
Company Profile Activity
Activity Insights
Peptomyc is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Peptomyc is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Peptomyc.
Peptomyc financials insights
Gather financial insights about Peptomyc, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$13.9M
Peptomyc Tech Stack
A closer look at the technologies used by Peptomyc
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
Events
Open Position
Funding
Peptomyc News & Media
Peptomyc's Omomyc-based therapy, OMO-103, has obtained approval for first-in-human phase I/II ...
Co-founded back in 2014 by VHIO’s Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, VHIO-born spin-off Peptomyc S.L . has just announced that it has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compoundPeptomyc’s Omomyc-based therapy, OMO-103, has obtained approval for first-in-human phase I/II trial to assess the efficacy and safety of a novel Myc inhibitor
BARCELONA, Spain, March 18, 2021 (GLOBE NEWSWIRE) -- Co-founded back in 2014 by VHIO’s Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, VHIO-born spin-off Peptomyc S.L. has just announced that it has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compound - a disruptive Myc inhibitor,Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board
Giacomo Di Nepi Giacomo Di Nepi assumes the role of Chairman of the Board at Peptomyc S.L.BARCELONA, Spain, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics targeting the Myc oncoprotein for cancer treatment, announces today that has appointed veteran pharma and biotech executive Giacomo Di Nepi as Chairman of the Board. Mr. Di Nepi has accumulated nearly 40 years of global experiencePeptomyc announces a new equity financing round of 11.4M€ led by AurorA Science and ...
Peptomyc announces a new equity financing round of 11.4M€ led by AurorA Science and supported by Alta Life Sciences, HealthEquity, CDTI and business angels
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Peptomyc
Sign Up For FreeTo access detailed company insights
Peptomyc is a pioneering biotechnology company focused on developing innovative MYC inhibitors to treat cancer, specifically utilizing mini-protein therapeutics to directly inhibit MYC, a key driver of cancer proliferation and resistance. The company aims to improve patient survival and quality of life for those with abnormal MYC activity through i... Read More
